Biblio

Maltagliati AJ, Paree JH, McIntosh KL, Moynahan KF, Vanderah TW.  2023.  Development and evaluation of a pre-clerkship spiral curriculum: data from three medical school classes.. Med Educ Online. 28(1):2167258.

Liktor-Busa E, Blawn KT, Kellohen KL, Wiese BM, Verkhovsky V, Wahl J, Vivek A, Palomino SM, Davis TP, Vanderah TW et al..  2020.  Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake.. PLoS One. 15(5):e0227463.

Zhang H, Largent-Milnes TM, Vanderah TW.  2020.  Glial neuroimmune signaling in opioid reward.. Brain Res Bull. 155:102-111.

Smith AF, Vanderah TW, Erickson RP.  2020.  Haploinsufficiency of tau decreases survival of the mouse model of Niemann-Pick disease type C1 but does not alter tau phosphorylation.. J Appl Genet. 61(4):567-570.

Johnston B, Vanderah TW.  2020.  Lost in the Haze: The Physician's Role in Cannabinoid Prescribing and Advising.. Am J Med. 133(1):7-8.

Ellingson HM, Vanderah TW.  2020.  Potential therapeutic treatments of cancer-induced bone pain.. Curr Opin Support Palliat Care. 14(2):107-111.

Thompson AL, Largent-Milnes TM, Vanderah TW.  2019.  Animal Models for the Study of Bone-Derived Pain.. Methods Mol Biol. 1914:391-407.

Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, Falk T, Bartlett MJ, Doyle KP, Konhilas JP.  2019.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.. J Pharmacol Exp Ther. 369(1):9-25.

Deekonda S, Cole J, Sunna S, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porecca F et al..  2016.  Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.. Bioorg Med Chem Lett. 26(1):222-7.

Giri AKumar, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F et al..  2015.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.

Petrov RR, Lee YSun, Vardanyan RS, Liu L, Ma S-W, Davis P, Lai J, Porreca F, Vanderah TW, Hruby VJ.  2013.  Effect of anchoring 4-anilidopiperidines to opioid peptides.. Bioorg Med Chem Lett. 23(11):3434-7.

Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma S-W, Vanderah TW et al..  2013.  Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.. Bioorg Med Chem Lett. 23(17):4975-8.

Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.

Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.

Largent-Milnes TM, Vanderah TW.  2010.  Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.